• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novomer relocates headquarters to Boston

Novomer relocates headquarters to Boston

July 3, 2017
CenterWatch Staff

Novomer, a sustainable chemicals company, has announced the relocation of its headquarters to One Bowdoin Square in Boston on July 17. The new office—designed to meet the expanded demands of the company’s growing bio-based chemicals business—will be in the heart of Boston, less than 20 miles from the current Waltham location.

The larger office space will provide room to grow and more space for collaboration. In addition to corporate offices, the new space will house business development and global project management activities, said Jim Mahoney, CEO of Novomer. “This move is about access,” explained Mahoney. “Greater access to public transportation for our employees and the closer location to Boston Logan International Airport will make it more convenient for partners, customers, and vendors to visit Novomer headquarters.”

Novomer is commercializing a family of competitively priced bio-based chemicals and high-performance polymers from ethanol and low-cost carbon monoxide. With its proprietary catalyst and process technology, Novomer enables these renewable feedstocks to be cost competitively transformed into chemical building blocks for a wide variety of industrial products and applications.

Effective July 17, the new address of Novomer’s headquarters will be One Bowdoin Square, Suite 300, Boston, MA, 02114. The company’s main phone number and email address will remain the same (781-419-9860, info@novomer.com).

Novomer Inc. is commercializing a family of high-performance, cost-effective, environmentally responsible polymers and chemicals based on proprietary catalyst technology. The company’s synthetic chemistry technology allows bio-based feedstocks such as ethanol to be combined with carbon monoxide to cost effectively produce chemicals and performance materials for a wide variety of industrial applications.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing